A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology
The LUME-Lung3 study is in 2 parts:
Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.
Phase II - Placebo controlled efficacy study of BIBF 1120 added to standard 3 weekly cycles of gemcitabine and cisplatin therapy in patients with at least Stable Disease after 2 previous courses of the chemotherapy
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
London、イギリス
- 1199.82.4401 Boehringer Ingelheim Investigational Site
-
Manchester、イギリス
- 1199.82.4402 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Milano、イタリア
- 1199.82.39004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Maastricht、オランダ
- 1199.82.3102 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona、スペイン
- 1199.82.3401 Boehringer Ingelheim Investigational Site
-
Madrid、スペイン
- 1199.82.3406 Boehringer Ingelheim Investigational Site
-
Málaga、スペイン
- 1199.82.3410 Boehringer Ingelheim Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
Run-in Phase I
- Histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent Non Small Cell Lung Cancer (NSCLC) with squamous cell histology.
- Measurable disease according to Response Evaluation Criteria in Solid Tumours ( RECIST 1.1).
- Patient Eastern Cooperative Oncology Group (ECOG) score of 0-1.
- Male or female patients age = 18 years.
- Life expectancy of at least three (3) months.
Written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines.
Phase II - in addition to the above criteria:
- Radiologically-confirmed at least stable disease after 2 prior cycles of cisplatin / gemcitabine chemotherapy.
Exclusion criteria:
- Prior therapy for advanced or metastatic or recurrent Non Small Cell Lung Cancer (NSCLC). One prior adjuvant, neoadjuvant or adjuvant + neoadjuvant treatment is allowed if at least 12 months have elapsed between the end of the treatment and randomization
- Prior treatment with other Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (other than bevacizumab)
- Any contraindications for treatment with gemcitabine and/or cisplatin.
- Use of any investigational drug within 4 weeks of entering the 1199.82 study.
- History of major thrombotic or clinically relevant bleeding event in the past 6 months.
- Significant cardiovascular diseases (i.e. hypertension not controlled by medication.
- Surgery within 4 weeks (except tumour biopsy) prior randomisation and incomplete wound healing.
- Active brain metastases
- Radiotherapy (except extremities) within 3 months prior to baseline imaging and radiotherapy for brain metastasis < 4 weeks prior baseline imaging.
- Any other current malignancy or malignancy diagnosed within the past five (5) years.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:BIBF 1120
VEGF inhibitor
|
VEGF阻害剤
|
プラセボコンパレーター:Placebo
BIBF 1120 placebo
|
BIBF 1120 placebo
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
時間枠:Up to 21 days from first drug administration
|
The following drug-related adverse events (AEs) qualified as a DLT: Non-hematological toxicity - Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 events excluding transient electrolyte abnormality, hyperuricemia and isolated elevation of gamma-glutamyl trans-peptidase.
Gastrointestinal AEs (nausea, vomiting, diarrhoea, abdominal pain) or hypertension of CTCAE Grade ≥3 despite optimal supportive care/intervention.
Alanine aminotransferase and or Aspartate aminotransferase elevation of CTCAE Grade ≥3.
Haematological toxicity - Uncomplicated CTCAE Grade 4 neutropenia (that was not associated with fever of ≥38.5°
Celsius) for >7 days (except during Cycle 1).
CTCAE Grade 4 febrile neutropenia associated with fever ≥38.5º
Celsius.
A decrease in platelet levels to CTCAE Grade 4 or CTCAE Grade 3 associated with bleeding or requiring transfusion.
The inability to resume nintedanib dosing within 14 days of stopping due to a drug-related AE was also considered a DLT.
|
Up to 21 days from first drug administration
|
Maximum Tolerated Dose (MTD) of Nintedanib Added to Cisplatin/Gemcitabine Based on the Occurrence of DLTs During Treatment Cycle 1.
時間枠:Up to 21 days from first drug administration
|
The MTD was defined as the dose of nintedanib administered with gemcitabine/cisplatin at which no more than 1 of 6 patients experienced DLT (or one dose tier below that dose at which 2 or more of 6 patients experienced DLT) during the first 21-day treatment cycle.
Any DLTs experienced after the start of the second treatment period were considered separately.
|
Up to 21 days from first drug administration
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Incidence of Adverse Events (AEs) According to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00
時間枠:From the first drug administration until 28 days after last study drug administration, up to 804 days
|
Incidence of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00 with grade 1-5.
|
From the first drug administration until 28 days after last study drug administration, up to 804 days
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
がん、非小細胞肺の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
BIBF1120の臨床試験
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)完了再発子宮体がん | 子宮内膜明細胞腺癌 | 子宮内膜漿液性腺癌 | 子宮内膜未分化がん | 子宮内膜腺癌 | 子宮内膜移行上皮がん | 子宮内膜粘液腺癌 | 子宮内膜扁平上皮がん | 悪性子宮体混合上皮性および間葉性新生物アメリカ
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)完了
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim完了再発非小細胞肺がん | IV期の非小細胞肺がん | 扁平上皮肺がん | III期の非小細胞肺がんアメリカ
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive Cancer Network完了再発結腸癌 | 再発直腸癌 | 直腸腺癌 | 結腸腺癌 | IVA期の結腸がん | IVA期の直腸がん | IVB期の結腸がん | ステージ IVB 直腸がんアメリカ
-
Roswell Park Cancer InstituteNational Comprehensive Cancer Network完了
-
Boehringer Ingelheim完了肺線維症アルゼンチン, オーストラリア, ベルギー, ブラジル, ブルガリア, カナダ, チリ, 中国, チェコ共和国, フランス, ドイツ, ギリシャ, ハンガリー, アイルランド, イタリア, 大韓民国, メキシコ, オランダ, ポルトガル, ロシア連邦, 南アフリカ, スペイン, 台湾, 七面鳥, イギリス